Vetoquinol (VETO): analysis and signal as of August 31, 2026
In short
The system assigns Vetoquinol (VETO) a weak signal, with a 1/1 vote and a score of 2.5 as of 31/08/2026. The main reason lies in the absence of live verified figures across the three analysis layers, despite a defensive sector profile supported by the macroeconomic convergence around the BCE rate of 2,25 %.
- Current signal
- weak (single draw, outside the three-draw protocol)
- Deterministic score
- +2.5 → signal expected by the scale : moderate (September 10, 2026)
Triggered rules
| Rule | Weight |
|---|---|
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| favors high gross profitability (gross profit / assets), a robust predictor of returns | +1.0 |
Thesis
The defensive sector bias of animal health and the macroeconomic convergence around the BCE rate of 2,25 % play in Vetoquinol's favour. However, none of the three analysis layers has validated the signal with live verified figures as of 31/08/2026. The fundamental layer remains silent, since revenue, EBIT, free cash flow and the PER for 2025 or 2026e have not been retrieved. The technical layer relies solely on an unverified local Yahoo statistic and reveals an overnight and intraday asymmetry that is structurally bearish. The risk and sentiment layer remains neutral by default due to a lack of usable news items. The verdict therefore downgrades confidence by one notch and the signal remains without validation until the Vetoquinol investor relations site or the Euronext database has released the recent URD and RFA.
Bull case
The main bullish argument rests on the defensive profile of the animal health sector and on the stock's ranking in the Favorises segment of the macro regime. Virbac (VIRP.PA), a direct comparable, reported T2 revenue up +7,2 % pcc over S1 2026, which sheds light on the sector dynamics. The market capitalisation above 1 Md EUR is confirmed by the TTF 0,3 % threshold. These elements outline a coherent sector foundation, albeit one not quantified for the stock itself.
Bear case
The main bearish argument remains the technical situation. The price trades below the MM200, with a gap of -7,8 %, and below the MM50, with a gap of -2,0 %. The asymmetry between overnight and intraday returns appears massive and persistent, with +91,4 % cumulative overnight versus -61,5 % cumulative intraday. This structure reflects a durably negative session dynamic. Moreover, the data comes from an unverified local Yahoo statistic, which weakens the reliability of the technical layer.
Scenarios
No quantified scenario appears in this verdict. Probabilities and targets remain unavailable due to a lack of validation of the fundamental and technical data as of 31/08/2026. This absence stems directly from the one-notch downgrade of confidence carried out by the system.
Risks
The main identified risks relate to data quality and freshness. The fundamental layer remains silent, depriving the analysis of revenue, EBIT, free cash flow and the PER for 2025 or 2026e. The technical layer relies on a single unverified source, while the overnight and intraday asymmetry, at +91,4 % cumulative overnight versus -61,5 % cumulative intraday, constitutes an unfavourable technical signal. The risk and sentiment layer, neutral by default due to a lack of usable news items, cannot detect an unanticipated piece of news before the release of the recent URD and RFA.
Upcoming catalysts
| Date | Description |
|---|---|
| T3 2026 revenue |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (3/3) | not published | |
| weak (single draw, outside the three-draw protocol) | unchanged | |
| weak (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
What signal does the system assign to Vetoquinol?
The system assigns a weak signal, supported by a 1/1 vote and a score of 2.5. This weakness reflects the absence of live verified figures across the three analysis layers as of 31/08/2026. The defensive bias of animal health and the macroeconomic convergence around the BCE rate of 2,25 % remain favourable, but no quantified validation comes to back them.
Why does the fundamental layer remain silent?
The reference data was not retrieved as of 31/08/2026: neither revenue, nor EBIT, nor free cash flow, nor the PER for 2025 or 2026e. The Vetoquinol investor relations site and the Euronext database have not yet released the recent URD and RFA. The thesis therefore relies on the technical layer and on the macro context, with the risk layer remaining neutral by default.
What does the technical layer show?
The price sits below the MM200, with a gap of -7,8 %, and below the MM50, with a gap of -2,0 %. The asymmetry between session and overnight remains massive and persistent: +91,4 % cumulative overnight versus -61,5 % cumulative intraday. However, the source remains an unverified local Yahoo statistic, which limits the reliability of the technical layer.
Which elements support the bullish thesis?
The animal health sector shows a defensive profile and the stock appears in the Favorises segment of the macro regime. Virbac (VIRP.PA), a direct comparable, reported T2 revenue up +7,2 % pcc over S1 2026. The market capitalisation exceeds 1 Md EUR, a threshold confirmed by the TTF 0,3 %. The macro convergence around the BCE rate of 2,25 % completes this foundation.
Which data would make it possible to consolidate the verdict?
The release of the recent URD and RFA by the Vetoquinol investor relations site or the Euronext database would be the priority. Also missing are revenue, EBIT, free cash flow and the PER for 2025 or 2026e, as well as usable news items to activate the risk and sentiment layer. Without these elements, confidence remains downgraded by one notch.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel (AMF · Informations réglementées périodiques)
- — Inside Information / News release on accounts, results (AMF · Informations réglementées continues)
- — Informations privilégiées / Communiqué sur comptes, résultats (AMF · Informations réglementées continues)
- — FORMULAIRE DE DECLARATION D'ACTIONS ET DE DROITS DE VOTE (AMF · Informations réglementées continues)
- — FORMULAIRE DE DECLARATION D'ACTIONS ET DE DROITS (AMF · Informations réglementées continues)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on August 31, 2026; this page was completed on September 2, 2026 at 21:08 (UTC).
- Interests: no position in the stock analysed (VETO) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: Airbus SE (AIR.PA)
- All analysed stocks
- Public methodology